SP142 evaluation contributes to the prediction of immune checkpoint inhibitor efficacy in non-small cell lung cancer with high PD-L1 expression assessed by 22C3.

However, our study showed a trend toward a longer OS in patients treated with combination therapy than with monotherapy as a first-line ICI treatment who had a 22C3 (C) ≥50% and SP142 TC0 and IC0; hence, if PD-L1 expression using the SP142 assay is negative, ICI combination therapy may be the better choice.

also in 53,322 other papers